A Holistic Approach to Insulin Resistance: Exploring the Link Between Fat Accumulation, Glucose Levels, and Personalized Metformin Dosage

 Abstract:

This paper explores the physiological and behavioral patterns observed over a 25-year period in an individual managing insulin resistance and associated weight gain. It investigates the disconnect between normal postprandial glucose readings and persistent fat accumulation, highlighting the role of underlying insulin resistance. Observations of metformin extended-release (XR) dosing strategies are discussed, particularly how subjective and objective metrics inform optimal dosage. The study also underscores the need for individualized treatment approaches that prioritize insulin sensitivity over glucose control alone.

---

1. Introduction
Insulin resistance (IR) is a metabolic condition wherein cells in muscles, fat, and liver become less responsive to insulin, resulting in impaired glucose uptake and increased fat storage. While hyperglycemia is commonly used to diagnose metabolic dysfunction, many individuals with IR maintain normal blood glucose readings while still experiencing significant weight gain. This phenomenon points to a deeper pathology that is often missed in standard diabetes screening protocols.

---

2. Background and Problem Statement
Conventional treatment of prediabetes and early-stage type 2 diabetes often involves monitoring blood sugar spikes and managing them through medications such as metformin. However, a lesser-known but equally important marker of metabolic dysfunction is how the body processes sugar, not just how much sugar is circulating in the blood.

In cases of insulin resistance, the pancreas secretes more insulin to maintain euglycemia (normal glucose levels), resulting in persistent hyperinsulinemia. Over time, excess insulin causes fat to accumulate, particularly visceral fat, even when fasting and post-meal glucose levels appear within normal ranges.

This paper explores how a patient maintained glucose levels within healthy ranges despite continuous fat gain due to hidden hyperinsulinemia and identifies metformin’s role not just as a glucose-lowering agent, but also as an insulin-sensitizer.

---

3. Observation and Methodology

3.1 Metformin Dosage Strategy
The patient was placed on a 1500mg daily dose of metformin XR, split into two doses of 750mg with breakfast and dinner. Self-monitoring of blood glucose (SMBG) using a glucometer showed post-meal readings consistently below 140 mg/dL — often between 90 and 100 mg/dL, even after carbohydrate-rich meals such as dates.

When an additional 250mg of metformin IR was added occasionally to aid weight loss, there was no significant observable benefit in fat reduction. This raised questions about dosage responsiveness and whether 1500mg was optimal or sub-optimal for reversing IR and promoting weight loss.

3.2 Glycemic Readings vs Fat Storage
Despite consistently normal sugar levels, the patient reported continued fat storage — a classic trait of insulin resistance. This paradox underscores a critical distinction: blood sugar may be under control, but insulin levels may still be excessively high, pushing energy into fat storage.

---

4. Key Findings

1. Normal Glucose ≠ Normal Metabolism
   Maintaining glucose below 140 mg/dL postprandially does not guarantee metabolic health. Insulin resistance can exist silently, leading to fat gain despite euglycemia.

2. Subjective and Objective Monitoring is Critical
   Relying solely on glucometer readings is insufficient. The body’s visual and visceral feedback — such as weight gain, energy levels, and fat distribution — are equally important in assessing IR.

3. Metformin and Weight Loss
   While metformin is proven to improve insulin sensitivity, its effect on weight loss is dose-dependent and highly individualized. Higher doses do not necessarily equate to better results if insulin resistance is not severe.

4. Individualized Treatment > Standard Dosing
   The ideal metformin dose appears to be the one that brings blood sugar stability without creating hypoglycemia, while also promoting fat mobilization over storage. In this case, 1500mg XR appeared to be sufficient for blood sugar control but may require long-term adherence or lifestyle synergy to impact fat loss.

---

5. Discussion
This case study emphasizes that insulin resistance is not solely a sugar problem — it is an insulin problem. Patients can appear normoglycemic while still experiencing all the harmful effects of metabolic syndrome, including weight gain and low energy. Treatment should be geared toward improving insulin sensitivity through diet, medication, and behavioral changes rather than reactive glucose control alone.

Importantly, it also brings to light that medication alone is not the full solution. The body’s feedback mechanisms (weight trends, fat distribution, post-meal energy slumps) can often reveal more than a glucometer can. In this study, doses beyond 1500mg showed diminishing returns, and lifestyle factors such as meal timing, macronutrient balance, and physical activity played a crucial role.

---

6. Conclusion
In managing insulin resistance, glucose readings can mislead if viewed in isolation. A deeper understanding of the body's insulin behavior is essential. Metformin remains an effective tool, but its true potential lies in combination with patient-driven, observation-based decision-making. Personalized medicine — where treatment adapts to the body’s real-time response — may be the key to reversing long-standing insulin resistance and its associated weight gain.

---

7. Recommendations for Further Study

• Clinical testing of fasting insulin and HOMA-IR scores to validate suspected hyperinsulinemia.

• Exploration of intermittent fasting and ketogenic strategies to reduce insulin load.

• Hormonal panels to assess cortisol and thyroid function, which may affect insulin dynamics.

• Inclusion of psychological stress markers, given their known role in IR development.